Analysis of the advantages of peritoneal dialysis in the treatment of chronic refractory heart failure
Análisis de las ventajas de la diálisis peritoneal en el tratamiento de la insuficiencia cardíaca refractaria crónica
Read
8491
Timeswas read the article
2281
Total PDF
6210
Total HTML
Share statistics
array:20 [ "pii" => "X2013251410050755" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Jul.10507" "estado" => "S300" "fechaPublicacion" => "2010-09-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:487-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4240 "formatos" => array:3 [ "EPUB" => 310 "HTML" => 3369 "PDF" => 561 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699510050758" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2010.Jul.10507" "estado" => "S300" "fechaPublicacion" => "2010-09-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2010;30:487-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10752 "formatos" => array:3 [ "EPUB" => 278 "HTML" => 9652 "PDF" => 822 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Análisis de las ventajas de la diálisis peritoneal en el tratamiento de la insuficiencia cardíaca refractaria crónica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "487" "paginaFinal" => "489" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Analysis of the advantages of peritoneal dialysis in the treatment of chronic refractory heart failure" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.E. Sánchez, C. Rodríguez, I. González, A. Fernández-Viña, M. Núñez, B. Peláez" "autores" => array:6 [ 0 => array:2 [ "Iniciales" => "J.E." "apellidos" => "Sánchez" ] 1 => array:2 [ "Iniciales" => "C." "apellidos" => "Rodríguez" ] 2 => array:2 [ "Iniciales" => "I." "apellidos" => "González" ] 3 => array:2 [ "Iniciales" => "A." "apellidos" => "Fernández-Viña" ] 4 => array:2 [ "Iniciales" => "M." "apellidos" => "Núñez" ] 5 => array:2 [ "Iniciales" => "B." "apellidos" => "Peláez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251410050755" "doi" => "10.3265/Nefrologia.pre2010.Jul.10507" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410050755?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510050758?idApp=UINPBA000064" "url" => "/02116995/0000003000000005/v0_201502091425/X0211699510050758/v0_201502091425/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251410050747" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Jul.10537" "estado" => "S300" "fechaPublicacion" => "2010-09-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:490-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8444 "formatos" => array:3 [ "EPUB" => 294 "HTML" => 7319 "PDF" => 831 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Ultrasound-guided renal biopsy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "490" "paginaFinal" => "492" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Biopsia renal ecodirigida" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Rivera Gorrin" "autores" => array:1 [ 0 => array:2 [ "Iniciales" => "M." "apellidos" => "Rivera Gorrin" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X021169951005074X" "doi" => "10.3265/Nefrologia.pre2010.Jul.10537" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169951005074X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410050747?idApp=UINPBA000064" "url" => "/20132514/0000003000000005/v0_201502091651/X2013251410050747/v0_201502091651/en/main.assets" ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Analysis of the advantages of peritoneal dialysis in the treatment of chronic refractory heart failure" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "487" "paginaFinal" => "489" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "J.E. Sánchez, C. Rodríguez, I. González, A. Fernández-Viña, M. Núñez, B. Peláez" "autores" => array:6 [ 0 => array:4 [ "Iniciales" => "J.E." "apellidos" => "Sánchez" "email" => array:1 [ 0 => "jesastur@hotmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "Iniciales" => "C." "apellidos" => "Rodríguez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:3 [ "Iniciales" => "I." "apellidos" => "González" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 3 => array:3 [ "Iniciales" => "A." "apellidos" => "Fernández-Viña" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 4 => array:3 [ "Iniciales" => "M." "apellidos" => "Núñez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 5 => array:3 [ "Iniciales" => "B." "apellidos" => "Peláez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Unidad de Diálisis Peritoneal. Área de Gestión Clínica de Nefro-Urología y Metabolismo Óseo y Mineral. Hospital Universitario Central de Asturias, Hospital Universitario Central de Asturias Oviedo, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Análisis de las ventajas de la diálisis peritoneal en el tratamiento de la insuficiencia cardíaca refractaria crónica" ] ] "textoCompleto" => "<p class="elsevierStylePara">Heart failure (HF) is a growing health problem in developed countries, and it is the terminal phase for many diseases. The prevalence of this condition in Spain is estimated to reach 6% in people over the age of 40 years old, increasing to 16% in people over 75.<span class="elsevierStyleSup">1 </span>HF is also associated with high comorbidities. This condition has been calculated to cause over 80,000 hospitalisations per year in our country, and it is the primary cause of hospitalisations in patients over 65 years old and responsible for 5% of all hospital admissions.<span class="elsevierStyleSup">2 </span>Lastly, HF is associated with high mortality rates. It is considered to be the third highest cause of cardiovascular deaths, behind ischemic heart disease and heart attacks.<span class="elsevierStyleSup">3 </span></p><p class="elsevierStylePara">HF is a progressive condition and can become lethal, even in patients that receive good treatment. The condition is characterised by a vicious circle which magnifies the symptoms of the condition and makes them continue indefinitely. The sympathetic neurohumoral and renin-angiotensin-aldosterone systems are activated as a consequence of renal hypoperfusion due to reduced cardiac output in patients with HF. This leads to renal vasoconstriction and an increase in water and sodium reabsorption in the proximal tubule. As such, it reduces the amount of water and sodium in the distal tubule, which diminishes the ability of the kidney to stimulate diuresis of the atrial natriuretic peptide and increases sensitivity to aldosterone.<span class="elsevierStyleSup">4 </span>This mechanism explains the resistance to the action of diuretics that occurs in patients with advanced HF. Consequently, the accumulation of water worsens HF and reduces cardiac output due to an increase in diastolic volume of the right ventricle.</p><p class="elsevierStylePara">Given this volume overload, any action taken to diminish overhydration will be beneficial for the patient. Some of the possible advantages are improved cardiac output (as a result of the Frank-Starling mechanism), as well as an increase in left ventricle and respiratory capacity.<span class="elsevierStyleSup">5 </span></p><p class="elsevierStylePara">In a recent review by Montejo et al.,<span class="elsevierStyleSup">6 </span>they presented the various therapies available for the treatment of this severe disease: pharmacological treatment, ultrafiltration using an extracorporeal blood circuit and peritoneal dialysis (PD). Almost at the same time, our group published our work with chronic diuretic treatment of patients with refractory HF using peritoneal dialysis.<span class="elsevierStyleSup">7 </span>This study included a large number of patients, the most numerous from the “icodextrin era.” Some important considerations to be taken into account for this study are the following:</p><p class="elsevierStylePara"><span class="elsevierStyleBold">FUNCTIONAL CLASS IMPROVEMENT </span></p><p class="elsevierStylePara">With the use of PD, all patients experienced a functional improvement, as evaluated using the New York Heart Association scale (NYHA); 65% of cases experienced a reduction of 2 levels, and the rest improved by one level. This improvement was produced without significant changes in the ejection fraction of the left ventricle (as measured by echocardiography), although there was a major decrease in systolic pressure in the pulmonary artery. No changes were observed in haematocrit or in kidney function.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">AFTER HOSPITALIZATION </span></p><p class="elsevierStylePara">One of the most salient aspects of patients in advanced stages of HF is the need for frequent hospitalizations, occasionally in intensive care units. The large majority of them are due to fluid overload, and only 5% of cases are due to reduced cardiac output.<span class="elsevierStyleSup">8 </span>The use of PD in diuretic treatment of patients with refractory HF results in a very marked decrease in hospitalization rates, which are reduced from 62 to 11 days/patient/year.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">MORTALITY </span></p><p class="elsevierStylePara">One worrying piece of data for patients with refractory HF is the high mortality observed in this group. We should point out that this study was performed with severely ill patients (Charlson index of 7.1; range: 4–10). Given the presence of both a poor cardiac situation and an elevated comorbidity rate, these patients were not expected to survive more than a year. In patients with refractory HF given conservative treatments (with various diuretic regimes) the published mean survival rate at 6 months is 50%, and at one year is barely above 25%.<span class="elsevierStyleSup">9 </span>In light of this bleak panorama, any measures we can take to improve the prognosis of these patients are welcome. The use of PD in our patients improved survival up to 82% at 12 months of treatment and 52% at 2 years. This information is crucially important, given that until now no improvement in survival was observed in studies using other types of treatment for this disease, such as tolvaptan,<span class="elsevierStyleSup">10 </span>nesitiride,<span class="elsevierStyleSup">11 </span>and extracorporeal ultrafiltration techniques.<span class="elsevierStyleSup">12 </span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">QUALITY OF LIFE </span></p><p class="elsevierStylePara">Few studies have evaluated the evolution of quality of life with the various treatments proposed for refractory HF. We evaluated quality of life in our patients using Euroquol 5D and SF-36 questionnaires. The use of PD is associated with an improved health as perceived by the patient (0.430 ± 0.221 versus 0.673 ± 0.093; p <0.01), a result also reflected in the results of the visual analogue scale, which passed from 4.5 ± 20.3 to 57.8 ± 25.8; p = 0.002. With regard to the SF­36 questionnaire, improvement was observed in all fields (reaching statistical significance in all except for general health, p = 0.079) and in the two component summaries. The health-related quality of life (HRQOL) survey taken before treatment was much lower than scores obtained from the general public (scores under 45), but reached values similar to those of the general populace after 6 months of treatment (scores over 45), except for in the field of general health. The prevalence of depression as defined by a mental summary score at or below 42 reached 73% before using this technique and was reduced to only 9% after just 6 months on this type of ultrafiltration. With regard to the effect size of the treatment, almost all of the SF-36 categories and values from the EQ-5D were greatly affected, except for the categories of general health, mental health, and the mental summary component, which were moderately affected; this all indicates a very relevant significance derived from this therapeutic method.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">COST-EFFECTIVENESS STUDIES </span></p><p class="elsevierStylePara">The sum of the costs borne by the patient in PD programs reaches €16,440, which is lower than the cost of supporting a conservative diuretic treatment (€27,551; p = 0.095). Taking into account all expenditures, the cost of personnel and hospitalizations were lower in the PD group. In contrast, the cost of consumables, lab tests, and imaging tests were lower in the other group. PD was associated with greater usefulness than the conservative treatment (0.673 compared to 0.430; p <0.01) regarding cost utility analysis. If we also take into account the lower cost implied by PD, the cost-utility analysis shows that the PD method has a cost of €23,305/quality-adjusted life year (QALY), whereas the conservative treatment has a cost of €81,053/QALY. Therefore, PD is the dominant strategy in terms of cost-utility, with a difference of €46.237 per QALY in favour of PD.</p><p class="elsevierStylePara">One limitation that must be taken into account for this study is that the sample size, although it is the largest yet published on the use of icodextrin, is only 17 patients. Performing a study with a larger sample size would provide greater weight to the results obtained and could confirm those produced in our study. Given the reduced number of patients that are treated in this manner at any given hospital, such a study would have to be a multi-centre effort. In our region, the increasing coverage of the results obtained with this type of treatment has motivated a greater number of patients to benefit from it. Currently, 28 patients have passed through our unit, confirming and improving the results so far described (unpublished data), including survival through longer follow-up periods.</p><p class="elsevierStylePara">Given these results, we consider PD to be an adequate diuretic treatment option for patients with refractory HF, given that it produces functional improvements, reduces hospitalisation rates and mortality, improves quality of life, and all of these results are produced at a reduced cost as compared to conventional treatments. It also provides a comfortable treatment technique for the patient that, in the majority of cases, consists of a single nocturnal exchange of icodextrin. The centres that treat heart failure should offer this treatment method to applicable patients in order to provide them with these benefits at a reduced health cost.</p>" "pdfFichero" => "P1-E503-S2273-A10507-EN.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:12 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Anguita Sánchez M, Crespo Leiro MG, De Teresa Galván E, Jiménez Navarro M, Alonso-Pulpón L, Muñiz García J. Prevalencia de la insuficiencia cardiaca en la población general española mayor de 45 años. Estudio PRICE. Rev Esp Cardiol 2008;61:1041-9." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Martínez-Sellés M, García Robles JA, Prieta L, Serrano JA, Muñoz R, Frades E, et al. Annual rates of admisión and seasonal variations in hospitalizations for Heart failure. Eur J Heart Fail) 2002; 4:779-86." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Rodríguez Artalejo F, Guallar Castillón P, Banegas Banegas JR, Rey Calero J. Trends in hospitalization and mortality for congestive heart failure in Spain, 1980-1993. Eur Heart J 1997;18:1771-9." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001;96:122-31. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11805379" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopresin. Am J Cardiol 2005;95:8B-13B. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15847852" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Montejo JD, Bajo MA, Del Peso G, Selgas R. Papel de la diálisis peritoneal en el tratamiento de la insuficiencia cardiaca refractaria. Nefrologia 2010;30: 21-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20098468" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sánchez JE, Ortega T, Rodríguez C, Díaz-Molina B, Martín M, García-Cueto C, et al.\u{A0}Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 2010;25:605-10. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19783594" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Krisham A, Oreopulos D. Peritoneal dialysis in congestive heart failure. Advances in Peritoneal Dialysis 2007;23:82-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17886609" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12748317" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Gheorgiade M, Konstam M, Burnett J, et al. Short term clinical effects of tolvaptan, an oral vasopressin antagonist in patients hospitalized for heart failure. The Everest clinical status trials. JAMA 2007;297:1332-43. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17384438" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kazory A, Ross E. Contemporary trends in the pharmacological and extracorporeal management of heart failure: A Nephrologic perspective. Circulation 2008;117:975-83. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18285578" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Costanzo MR, Guglin M, Saltzberg M, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute descompensated heart failure. J Am Coll Cardiol 2007;49:675-83. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17291932" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003000000005/v0_201502091651/X2013251410050755/v0_201502091651/en/main.assets" "Apartado" => array:4 [ "identificador" => "35429" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorials" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003000000005/v0_201502091651/X2013251410050755/v0_201502091651/en/P1-E503-S2273-A10507-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410050755?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 9 | 9 | 18 |
| 2024 October | 62 | 29 | 91 |
| 2024 September | 62 | 26 | 88 |
| 2024 August | 83 | 53 | 136 |
| 2024 July | 67 | 43 | 110 |
| 2024 June | 70 | 38 | 108 |
| 2024 May | 81 | 30 | 111 |
| 2024 April | 61 | 30 | 91 |
| 2024 March | 67 | 22 | 89 |
| 2024 February | 67 | 34 | 101 |
| 2024 January | 56 | 35 | 91 |
| 2023 December | 55 | 29 | 84 |
| 2023 November | 63 | 34 | 97 |
| 2023 October | 74 | 48 | 122 |
| 2023 September | 87 | 27 | 114 |
| 2023 August | 62 | 25 | 87 |
| 2023 July | 51 | 23 | 74 |
| 2023 June | 47 | 35 | 82 |
| 2023 May | 43 | 34 | 77 |
| 2023 April | 45 | 15 | 60 |
| 2023 March | 49 | 25 | 74 |
| 2023 February | 41 | 11 | 52 |
| 2023 January | 35 | 28 | 63 |
| 2022 December | 70 | 34 | 104 |
| 2022 November | 61 | 33 | 94 |
| 2022 October | 59 | 46 | 105 |
| 2022 September | 44 | 34 | 78 |
| 2022 August | 59 | 50 | 109 |
| 2022 July | 25 | 40 | 65 |
| 2022 June | 67 | 40 | 107 |
| 2022 May | 51 | 28 | 79 |
| 2022 April | 36 | 50 | 86 |
| 2022 March | 47 | 59 | 106 |
| 2022 February | 32 | 45 | 77 |
| 2022 January | 32 | 30 | 62 |
| 2021 December | 46 | 31 | 77 |
| 2021 November | 38 | 33 | 71 |
| 2021 October | 79 | 54 | 133 |
| 2021 September | 33 | 35 | 68 |
| 2021 August | 47 | 38 | 85 |
| 2021 July | 61 | 31 | 92 |
| 2021 June | 41 | 25 | 66 |
| 2021 May | 36 | 37 | 73 |
| 2021 April | 61 | 39 | 100 |
| 2021 March | 52 | 34 | 86 |
| 2021 February | 41 | 12 | 53 |
| 2021 January | 38 | 21 | 59 |
| 2020 December | 31 | 19 | 50 |
| 2020 November | 32 | 11 | 43 |
| 2020 October | 19 | 10 | 29 |
| 2020 September | 13 | 7 | 20 |
| 2020 August | 49 | 20 | 69 |
| 2020 July | 39 | 13 | 52 |
| 2020 June | 26 | 15 | 41 |
| 2020 May | 53 | 21 | 74 |
| 2020 April | 25 | 16 | 41 |
| 2020 March | 42 | 20 | 62 |
| 2020 February | 46 | 19 | 65 |
| 2020 January | 44 | 15 | 59 |
| 2019 December | 56 | 29 | 85 |
| 2019 November | 32 | 19 | 51 |
| 2019 October | 21 | 10 | 31 |
| 2019 September | 46 | 16 | 62 |
| 2019 August | 34 | 15 | 49 |
| 2019 July | 53 | 23 | 76 |
| 2019 June | 37 | 20 | 57 |
| 2019 May | 43 | 21 | 64 |
| 2019 April | 50 | 29 | 79 |
| 2019 March | 33 | 22 | 55 |
| 2019 February | 29 | 16 | 45 |
| 2019 January | 30 | 20 | 50 |
| 2018 December | 71 | 26 | 97 |
| 2018 November | 87 | 16 | 103 |
| 2018 October | 67 | 9 | 76 |
| 2018 September | 60 | 17 | 77 |
| 2018 August | 38 | 10 | 48 |
| 2018 July | 36 | 6 | 42 |
| 2018 June | 43 | 13 | 56 |
| 2018 May | 42 | 10 | 52 |
| 2018 April | 50 | 8 | 58 |
| 2018 March | 50 | 9 | 59 |
| 2018 February | 52 | 8 | 60 |
| 2018 January | 53 | 9 | 62 |
| 2017 December | 51 | 12 | 63 |
| 2017 November | 27 | 12 | 39 |
| 2017 October | 45 | 10 | 55 |
| 2017 September | 33 | 9 | 42 |
| 2017 August | 33 | 7 | 40 |
| 2017 July | 33 | 13 | 46 |
| 2017 June | 25 | 4 | 29 |
| 2017 May | 45 | 10 | 55 |
| 2017 April | 32 | 7 | 39 |
| 2017 March | 27 | 18 | 45 |
| 2017 February | 27 | 6 | 33 |
| 2017 January | 12 | 7 | 19 |
| 2016 December | 50 | 11 | 61 |
| 2016 November | 61 | 3 | 64 |
| 2016 October | 103 | 7 | 110 |
| 2016 September | 108 | 3 | 111 |
| 2016 August | 193 | 7 | 200 |
| 2016 July | 165 | 6 | 171 |
| 2016 June | 117 | 0 | 117 |
| 2016 May | 125 | 0 | 125 |
| 2016 April | 101 | 0 | 101 |
| 2016 March | 64 | 0 | 64 |
| 2016 February | 86 | 0 | 86 |
| 2016 January | 82 | 0 | 82 |
| 2015 December | 100 | 0 | 100 |
| 2015 November | 86 | 0 | 86 |
| 2015 October | 62 | 0 | 62 |
| 2015 September | 62 | 0 | 62 |
| 2015 August | 76 | 0 | 76 |
| 2015 July | 65 | 0 | 65 |
| 2015 June | 33 | 0 | 33 |
| 2015 May | 51 | 0 | 51 |
| 2015 April | 5 | 0 | 5 |
Show all
